1801 Augustine Cutoff
9 articles with Incyte
Phase 2 GEOMETRY mono-1 Trial of Investigational Medicine Capmatinib Shows Positive Results in Patients with MET-mutated Advanced NSCLC
Phase 2 study efficacy data showed overall response rate of 72.0 percent and 39.1 percent, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping mutated non-small cell lung cancer (NSCLC)
Incyte Announces Data for Pemigatinib, its Selective FGFR Inhibitor, to be Featured at the ESMO 2018 Congress
Interim Phase 2 results highlight the potential of pemigatinib (INCB54828) in cholangiocarcinoma and urothelial carcinoma.
IMV Inc. Announces Phase 2 Basket Trial in Collaboration with Merck to Evaluate DPX-Survivac in Combination with KEYTRUDA® Across Five Solid Tumor Indications
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it has expanded its clinical program with a Phase 2 basket trial evaluating its lead candidate, DPX-Survivac, in combination with low dose cyclophosphamide and Merck’s anti-PD-1 therapy,
Incyte Corporation announced today that it will present at the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13, 2018 at 10:00 am EDT in New York.
NewLink Genetics has announced, with the company restructuring and layoffs, they are refocusing on indoximod.
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them, such as pancreas cells to cure type 1 diabetes and failed clinical trials cast doubt on new immuno-oncology targets.
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.
In 2015, Bristol-Myers Squibb acquired Flexus Biosciences for about $1.25 billion, picking up F001287, Flexus’ IDO1 inhibitor in the bargain, as well as its IDO/TDO discovery program. Now, Bristol-Myers has dropped two Phase III clinical trials of the IDO1 inhibitor it acquired.